Applying a radiomics approach to predict prognosis of lung cancer patients

Radiomics is an emerging technology to decode tumor phenotype based on quantitative analysis of image features computed from radiographic images. In this study, we applied Radiomics concept to investigate the association among the CT image features of lung tumors, which are either quantitatively computed or subjectively rated by radiologists, and two genomic biomarkers namely, protein expression of the excision repair cross-complementing 1 (ERCC1) genes and a regulatory subunit of ribonucleotide reductase (RRM1), in predicting disease-free survival (DFS) of lung cancer patients after surgery. An image dataset involving 94 patients was used. Among them, 20 had cancer recurrence within 3 years, while 74 patients remained DFS. After tumor segmentation, 35 image features were computed from CT images. Using the Weka data mining software package, we selected 10 non-redundant image features. Applying a SMOTE algorithm to generate synthetic data to balance case numbers in two DFS (“yes” and “no”) groups and a leave-one-case-out training/testing method, we optimized and compared a number of machine learning classifiers using (1) quantitative image (QI) features, (2) subjective rated (SR) features, and (3) genomic biomarkers (GB). Data analyses showed relatively lower correlation among the QI, SR and GB prediction results (with Pearson correlation coefficients < 0.5 including between ERCC1 and RRM1 biomarkers). By using area under ROC curve as an assessment index, the QI, SR and GB based classifiers yielded AUC = 0.89±0.04, 0.73±0.06 and 0.76±0.07, respectively, which showed that all three types of features had prediction power (AUC>0.5). Among them, using QI yielded the highest performance.

[1]  Asger Dirksen,et al.  Screening for Lung Cancer With Low-Dose Computed Tomography , 2014, Annals of Internal Medicine.

[2]  Heinz-Otto Peitgen,et al.  Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans , 2006, IEEE Transactions on Medical Imaging.

[3]  Henry Li,et al.  Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  Vassilis Georgoulias,et al.  How close are we to customizing chemotherapy in early non-small cell lung cancer? , 2011, Therapeutic advances in medical oncology.

[5]  David Gur,et al.  Direct assessment of lung function in COPD using CT densitometric measures , 2014, Physiological measurement.

[6]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[7]  David Gur,et al.  Performance change of mammographic CAD schemes optimized with most-recent and prior image databases. , 2003, Academic radiology.

[8]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[9]  Russel Pears,et al.  Synthetic Minority Over-sampling TEchnique (SMOTE) for Predicting Software Build Outcomes , 2014, SEKE.

[10]  Wei Qian,et al.  Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients , 2016, IEEE Transactions on Biomedical Engineering.

[11]  Thomas E. Yankeelov,et al.  Quantitative multimodality imaging in cancer research and therapy , 2014, Nature Reviews Clinical Oncology.

[12]  Nitesh V. Chawla,et al.  SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..

[13]  M. Vázquez,et al.  Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. , 2003, Chest.

[14]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[15]  A. Jackson,et al.  Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. , 2008, The Lancet. Oncology.

[16]  Zhong Zheng,et al.  ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. , 2011, The American journal of pathology.

[17]  C. Begg,et al.  Computed Tomography Screening and Lung Cancer Outcomes , 2008 .

[18]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[19]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[20]  Sunil Singhal,et al.  Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.

[21]  Wei Qian,et al.  Computer-aided breast MR image feature analysis for prediction of tumor response to chemotherapy. , 2015, Medical physics.

[22]  Qiang Li,et al.  Reduction of bias and variance for evaluation of computer-aided diagnostic schemes. , 2006, Medical physics.

[23]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[24]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.